Methyl-Beta-Cyclodextrin Restores Aberrant Bone Morphogenetic Protein
Today’s cyclodextrin is about their potential in osteoporosis.
This paper was published by University of Delaware who found that after treating bone marrow stromal cells with methyl-β-cyclodextrin, a disruptor of cellular endocytosis, bone morphogenetic protein (BMP) signaling is restored in 15-month-old mice, as shown by von Kossa assays.
MβCD has the potential to restore BMP receptor type Ia function, and the BMP signaling pathway offers a promising avenue for future OP therapies.
Congrats to Daniel Halloran, Venu Pandit, Kelechi Blessing Chukwuocha and Anja Nohe for their great work!
